Duke University

US Government As Represented by the Secretary of the Army

Children's Medical Center Corporation

Georgia D Tomaras

Barton F Haynes

Stephen C Harrison

Dani Paul Bolognesi

Kent J Weinhold

Michael L Greenberg

Jerome H Kim

Nelson L Michael

Simon F Lacey

Hua-Xin Liao

Feng Gao

M Anthony Moody

S Munir Alam

David C Montefiori

Xiaoying Shen

Moses D Sekaran

Sallie Permar

The invention provides compositions and methods to induce and boost antibody response, including but not limited to IgG responses binding to HIV-1 in a subject in need thereof, wherein the induced/boosted plasma level of the antibody responses, for example V3 and/or CD4 binding site antibody responses, is over a threshold level and is associated with reduced risk of maternal-to-child-transmission (MTCT) of HIV-1.

Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies

The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.

Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use

Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens

The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such formulations.

Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions

The present invention relates to a bioactive molecule, herein referred to as the CD8suppressor molecule, that is produced by the CD8subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8suppressor molecule. The CD8suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.

Methods for identification of CDS8+ suppressor molecules

The present invention relates to a bioactive molecule, herein referred to as the CD8 suppressor molecule, that is produced by the CD8 subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8 cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8 suppressor molecule. The CD8 suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.

Suppressor of HIV replication and transcription

Growing community of inventors

Durham, NC, United States of America

Georgia D Tomaras